Eli Lilly Takes First Legal Action Against Black Market for Experimental Obesity Drug Retatrutide on August 13, 2026 black market Clinical Trials compounding pharmacies Eli Eli Lilly lawsuits medical spas obesity drug online sellers Phase 3 retatrutide U.S. Justice Department unapproved United States Food and Drug Administration +
Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path on August 11, 2026 6-minute walk distance levosimendan Multiple Acyl Coenzyme A Dehydrogenase Deficiency PH-HFpEF primary endpoint Tenax Therapeutics Type C meeting U.S. unapproved United States Food and Drug Administration +
Explaining unapproved drugs to payors: FDA offers pharma new guidance to avoid pitfalls on June 11, 2026 Advice Communication control act - information payors unapproved United States Food and Drug Administration +